|
|
 |
|
Viewing report
|
|
|
|
Recalibrating Goals Can Lead to Better Outcomes in Academic/Industry Biomarker and Diagnostics Collaborations
Decision Resources, Inc, Oct 2011
Somewhere in between the publication of data regarding a new biomarker or diagnostic test and the launch of an approved product for the clinic lies the area in which academic institutions and industry entities must reconcile their typical measures of success. While academia’s goal of publication may pique the interest of industry, the work (and capital) required to move from publication to a final, market-approved test - industry’s goal - is substantial. Communication of goals is necessary for both parties in a collaboration to understand the full extent of one another’s desires and capabilities.
Questions answered in this report:
- Various relationships exist between academic institutions and industry engaged in biomarker and diagnostics development. What are the most common types of partnerships between academia and industry?
- Collaborations are focused on a variety of therapeutic areas, but some are much more common than others. Which therapeutic areas have the greatest number of biomarker/diagnostics collaborations?
- Industrial science and academic science have fundamentally different orientations, as well as different cultures and rules of conduct. What are the issues to consider before embarking on a partnership? What are the ingredients for a successful industry-academia relationship?
Scope:
Dealmaking assessment: Snapshot of academic/industry biomarker and diagnostics collaborations from January 2009 through June 2011.
Sidebars: Innovative Medicines Initiative, Collaborative Models in the Pharmaceutical Industry.
Commercial biomarker development: Creating a win-win for academia and industry; the negotiation process; caveats for successful relationships.
Types of academia-industry relationships: Sponsorship, consultation, consortia, partnerships and collaborations, and spin-outs.
|
|
|
|
